Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation von Giles, Francis J., Kantarjian, Hagop M., Kornblau, Steve M., Thomas, Deborah A., Garcia‐Manero, Guillermo, Waddelow, Tracey A., David, Cynthia L., Phan, Alexandria T., Colburn, Dawn E., Rashid, Asif, Estey, Elihu H.

Volltext

Intravenous Corticosteroids to Reduce Gemtuzumab Ozogamicin Infusion Reactions von Giles, Francis J, Cortes, Jorge E, Halliburton, Terri A, Mallard, Susie J, Estey, Elihu H, Waddelow, Tracey A, Lim, JoAnn T

Volltext

Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasm... von Tsimberidou, Apostolia-Maria, Waddelow, Tracey, Kantarjian, Hagop M, Albitar, Maher, Giles, Francis J

Volltext

Hydroxyurea accelerates loss of extrachromosomally amplified genes from tumor cells von VON HOFF, D. D, WADDELOW, T, FORSETH, B, DAVIDSON, K, SCOTT, J, WAHL, G

Volltext